We are live on ! Find out more
Daiwa Securities Group

Daiwa Securities Group Portfolio holdings

AUM $34.8B
1-Year Est. Return 20.7%
This Fund
S&P 500
This Quarter Est. Return
+1.69%
1 Year Est. Return
+20.7%
3 Year Est. Return
+66.64%
5 Year Est. Return
+79.21%
10 Year Est. Return
+192.59%
AUM
$22.4B
AUM Growth
+$745M
Cap. Flow
+$687M
Cap. Flow %
3.07%
Top 10 Hldgs %
31.51%
Holding
1,352
New
72
Increased
666
Reduced
342
Closed
71

Top Buys

Rank Stock Value
1
AMT icon
American Tower
AMT
+$191M
2
MSFT icon
Microsoft
MSFT
+$116M
3
NVDA icon
NVIDIA
NVDA
+$115M
4
AAPL icon
Apple
AAPL
+$108M
5
WY icon
Weyerhaeuser
WY
+$83.8M

Top Sells

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$118M
2
DLR icon
Digital Realty Trust
DLR
+$106M
3
CCI icon
Crown Castle
CCI
+$104M
4
SPG icon
Simon Property Group
SPG
+$93M
5
KIM icon
Kimco Realty
KIM
+$64.5M

Sector Composition

Rank Sector Weight
1 Real Estate 37.54%
2 Technology 23.33%
3 Communication Services 8.01%
4 Consumer Discretionary 6.37%
5 Financials 5.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KROS icon
1201
Keros Therapeutics
KROS
$197M
$2K ﹤0.01%
133
– –
MESO
1202
Mesoblast
MESO
$1.84B
$2K ﹤0.01%
+105
New +$1.16K
MLYS icon
1203
Mineralys Therapeutics
MLYS
$2.35B
$2K ﹤0.01%
152
– –
DFTX
1204
Definium Therapeutics
DFTX
$5.52B
$2K ﹤0.01%
+242
New +$1.67K
OABI icon
1205
OmniAb
OABI
$284M
$2K ﹤0.01%
475
– –
OMER icon
1206
Omeros
OMER
$834M
$2K ﹤0.01%
+191
New +$1.31K
ORIC icon
1207
Oric Pharmaceuticals
ORIC
$1.16B
$2K ﹤0.01%
249
– –
PACB icon
1208
Pacific Biosciences
PACB
$435M
$2K ﹤0.01%
909
– –
PHAT icon
1209
Phathom Pharmaceuticals
PHAT
$932M
$2K ﹤0.01%
260
– –
REPL icon
1210
Replimune Group
REPL
$422M
$2K ﹤0.01%
200
– –
RLAY icon
1211
Relay Therapeutics
RLAY
$3.93B
$2K ﹤0.01%
486
– –
RNAC icon
1212
Cartesian Therapeutics
RNAC
$223M
$2K ﹤0.01%
+84
New +$1.7K
SIGA icon
1213
SIGA Technologies
SIGA
$237M
$2K ﹤0.01%
270
– –
STOK icon
1214
Stoke Therapeutics
STOK
$1.81B
$2K ﹤0.01%
+175
New +$2.15K
SVRA icon
1215
Savara
SVRA
$1.08B
$2K ﹤0.01%
553
– –
TBPH icon
1216
Theravance Biopharma
TBPH
$876M
$2K ﹤0.01%
215
– –
THRD
1217
DELISTED
Third Harmonic Bio
THRD
$2K ﹤0.01%
149
– –
TRML
1218
DELISTED
Tourmaline Bio
TRML
$2K ﹤0.01%
95
– –
URGN icon
1219
UroGen Pharma
URGN
$1.95B
$2K ﹤0.01%
160
– –
RAPP
1220
Rapport Therapeutics
RAPP
$1.99B
$2K ﹤0.01%
+121
New +$2.68K
GRAL
1221
GRAIL Inc
GRAL
$2.67B
$2K ﹤0.01%
98
– –
ORKA
1222
Oruka Therapeutics
ORKA
$5.3B
$2K ﹤0.01%
+116
New +$2.83K
FVR
1223
FrontView REIT
FVR
$491M
$2K ﹤0.01%
+93
New +$1.76K
ABUS icon
1224
Arbutus Biopharma
ABUS
$853M
$1K ﹤0.01%
395
– –
ALEC icon
1225
Alector
ALEC
$169M
$1K ﹤0.01%
277
– –
47 48
49
50 51

Similar funds

SAM
Storebrand Asset Management Lysaker, Norway $34.8B AUM 25.49% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
VIA
Vanguard Investments Australia Victoria, Australia $34.6B AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Daiwa Securities Group's Q4 2024 Portfolio in Review

As of Q4 2024, Daiwa Securities Group held 1,352 positions worth $22.4B, up 3.4% from $21.6B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Daiwa Securities Group deployed $687M of net new capital in Q4 2024, opening 72 new positions and adding to 666 existing holdings. Its largest new stake was Curbline Properties: 2,033,334 shares worth $47.2M.

By sector, the portfolio is most concentrated in Real Estate at 38% of assets, down from 42% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was iShares Core S&P 500 ETF, an estimated $118M trimmed.

  • Daiwa Securities Group's largest Q4 2024 buy was Curbline Properties: 2,033,334 shares worth $47.2M.
  • Daiwa Securities Group added most to American Tower in Q4 2024, an estimated $191M increase.
  • Daiwa Securities Group's biggest Q4 2024 reduction was iShares Core S&P 500 ETF, cutting an estimated $118M.
  • Daiwa Securities Group fully exited State Street SPDR S&P 500 ETF Trust in Q4 2024, selling an estimated $10.3M.
  • Daiwa Securities Group's ten largest holdings make up 32% of its $22.4B portfolio in Q4 2024.
  • Daiwa Securities Group opened 72 new positions and closed 71 in Q4 2024.
  • Daiwa Securities Group's portfolio value rose 3.4% quarter-over-quarter to $22.4B.

Based on Daiwa Securities Group's 13F filing for Q4 2024, filed 7 Feb 2025.